Literature DB >> 22310064

Polymorphisms of LTA, LGALS2, and PSMA6 genes and coronary atherosclerosis: a pathological study of 1503 consecutive autopsy cases.

Shinobu Ikeda1, Noriko Tanaka, Tomio Arai, Kouji Chida, Masaaki Muramatsu, Motoji Sawabe.   

Abstract

OBJECTIVE: Recent genome-wide association studies have identified polymorphisms of lymphotoxin-α (LTA), galectin-2 (LGALS2), and proteasome subunit a type 6 (PSMA6) genes as genetic risk factors for myocardial infarction (MI). However, their effects on coronary atherosclerosis, an intermediate phenotype of MI, remain largely unknown.
METHODS: We investigated the correlation between polymorphisms of the LTA, LGALS2, and PSMA6 genes and the severity of pathological coronary stenosis index (CSI) and MI in 1503 consecutive autopsy cases of Japanese elderly patients.
RESULTS: The polymorphisms LTA rs1041981 and LGALS2 rs7291467 were associated with CSI with odds ratios of 1.54 (95% CI, 1.17-2.01; AA+CA over CC) and 1.62 (95% CI, 1.11-2.37; TT over CC+CT), respectively. PSMA6 rs1048990 was not associated with CSI. None of the SNPs was associated with MI in our sample.
CONCLUSION: Our findings indicate that the LTA and LGALS2 polymorphisms affect the subclinical phenotype of the coronary artery, which predisposes to the incidence of MI.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310064     DOI: 10.1016/j.atherosclerosis.2012.01.003

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Association between LGALS2 3279C>T and coronary artery disease: A case-control study and a meta-analysis.

Authors:  Jiangfang Lian; Peiliang Fang; Dongjun Dai; Yanna Ba; Xi Yang; Xiaoyan Huang; Junxin Li; Xiaoliang Chen; Jian Guo; Feng Guan; Ping Peng; Ruochi Zhao; Shangshi Zhang; Fang Gao; Linlin Tang; Cheng Zhang; Huihui Ji; Qingxiao Hong; Huadan Ye; Limin Xu; Qilong Zhong; Panpan Liu; Jianqing Zhou; Shiwei Duan
Journal:  Biomed Rep       Date:  2014-08-04

2.  Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy.

Authors:  Fay Wright; Marilyn Hammer; Steven M Paul; Bradley E Aouizerat; Kord M Kober; Yvette P Conley; Bruce A Cooper; Laura B Dunn; Jon D Levine; Gail DEramo Melkus; Christine Miaskowski
Journal:  Cytokine       Date:  2017-01-19       Impact factor: 3.861

3.  Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk.

Authors:  Hairong Wang; Mei Jiang; Hua Zhu; Qihong Chen; Peihua Gong; Jie Lin; Jide Lu; Jianping Qiu
Journal:  Mol Biol Rep       Date:  2012-10-31       Impact factor: 2.316

4.  Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies.

Authors:  Xi Yu; Yi Huang; Changhong Li; Hailian Yang; Caide Lu; Shiwei Duan
Journal:  Tumour Biol       Date:  2013-10-18

5.  Association of obesity with proteasomal gene polymorphisms in children.

Authors:  Sarmite Kupca; Tatjana Sjakste; Natalija Paramonova; Olga Sugoka; Irena Rinkuza; Ilva Trapina; Ilva Daugule; Alfred J Sipols; Ingrida Rumba-Rozenfelde
Journal:  J Obes       Date:  2013-12-21

6.  PSMA6 (rs2277460, rs1048990), PSMC6 (rs2295826, rs2295827) and PSMA3 (rs2348071) genetic diversity in Latvians, Lithuanians and Taiwanese.

Authors:  Tatjana Sjakste; Natalia Paramonova; Lawrence Shi-Shin Wu; Zivile Zemeckiene; Brigita Sitkauskiene; Raimundas Sakalauskas; Jiu-Yao Wang; Nikolajs Sjakste
Journal:  Meta Gene       Date:  2014-04-17

7.  Long-term outdoor air pollution and DNA methylation in circulating monocytes: results from the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Gloria C Chi; Yongmei Liu; James W MacDonald; R Graham Barr; Kathleen M Donohue; Mark D Hensley; Lifang Hou; Charles E McCall; Lindsay M Reynolds; David S Siscovick; Joel D Kaufman
Journal:  Environ Health       Date:  2016-12-01       Impact factor: 5.984

8.  Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity.

Authors:  Jamie Kane; Matthijs Jansen; Sebastian Hendrix; Laura A Bosmans; Linda Beckers; Claudia van Tiel; Marion Gijbels; Noam Zelcer; Carlie J de Vries; Philipp von Hundelshausen; Marc Vervloet; Ed Eringa; Anton J Horrevoets; Niels van Royen; Esther Lutgens
Journal:  Thromb Haemost       Date:  2022-02-08       Impact factor: 6.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.